A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension
The aim of this study was to evaluate differences in the persistency and treatment costs for latanoprost, bimatoprost, or beta-blockers in open-angle glaucoma or ocular hypertensive patients. This study was a retrospective, multicenter, parallel, active-controlled comparison of patients who were pre...
Gespeichert in:
| Veröffentlicht in: | Journal of ocular pharmacology and therapeutics 2004-10, Vol.20 (5), p.383-392 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 392 |
|---|---|
| container_issue | 5 |
| container_start_page | 383 |
| container_title | Journal of ocular pharmacology and therapeutics |
| container_volume | 20 |
| creator | DAY, Douglas G SCHACKNOW, Paul N SHARPE, Elizabeth D ELLYN, John C KULZE, John C THRELKELD, Anisa B JONES, Evan D BROWN, Reay H JENKINS, Jessica N STEWART, William C |
| description | The aim of this study was to evaluate differences in the persistency and treatment costs for latanoprost, bimatoprost, or beta-blockers in open-angle glaucoma or ocular hypertensive patients.
This study was a retrospective, multicenter, parallel, active-controlled comparison of patients who were prescribed with ocular hypotensive monotherapy between September 1996 and August 2002.
1,182 patients were included. The Kaplan Meier life table analysis showed that latanoprost was continued longest among the groups for the first year of therapy (p=0.02). A significant difference existed between groups in the final intraocular pressure for latanoprost (17.3+/-3.9, N=357), for bimatoprost (18.0+/-3.6, N=146), and for the beta-blockers (17.9+/-3.7, N=335) (p= |
| doi_str_mv | 10.1089/jop.2004.20.383 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67222977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67222977</sourcerecordid><originalsourceid>FETCH-LOGICAL-c238t-b954e1108258d36c9410d0752ae867bd287061a3c25914068c87965417ecf44d3</originalsourceid><addsrcrecordid>eNpFkctu1TAQhi1ERcuBNTvkDazIqS_xJcuq4iZVYlPW0cRxWhfHDrEjdB6i79w56kHdjD3yPzP-5ifkA2d7zmx3-ZCXvWCsxbCXVr4iF1wp0xgjxWu8M8sao608J29LeWCMS6b5G3LOlVZMcXlBHq_o4tcSSvXJHSikkXqXU56DwwTiAZ9onmiECikvay71Cx3CDPV_klc6-ArNELP7g61oSHSBGnyqhf4L9Z7mxacG0l309C7C5vIMx6rstggrvT_gB3B6CTm9I2cTxOLfn84d-f3t6-31j-bm1_ef11c3jRPS1mboVOs50gllR6ld13I2MqMEeKvNMAprkBOkE6rjLdPWWdNp1XLj3dS2o9yRz899keHv5kvt51CcjxGSz1vptRFCdLjFHbl8FjqELauf-mVF-PXQc9YfHejRgf7oAIYeHcCKj6fW2zD78UV_WjkKPp0EUBzEaYXkQnnRaSER0sgntpqQpg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67222977</pqid></control><display><type>article</type><title>A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><creator>DAY, Douglas G ; SCHACKNOW, Paul N ; SHARPE, Elizabeth D ; ELLYN, John C ; KULZE, John C ; THRELKELD, Anisa B ; JONES, Evan D ; BROWN, Reay H ; JENKINS, Jessica N ; STEWART, William C</creator><creatorcontrib>DAY, Douglas G ; SCHACKNOW, Paul N ; SHARPE, Elizabeth D ; ELLYN, John C ; KULZE, John C ; THRELKELD, Anisa B ; JONES, Evan D ; BROWN, Reay H ; JENKINS, Jessica N ; STEWART, William C</creatorcontrib><description>The aim of this study was to evaluate differences in the persistency and treatment costs for latanoprost, bimatoprost, or beta-blockers in open-angle glaucoma or ocular hypertensive patients.
This study was a retrospective, multicenter, parallel, active-controlled comparison of patients who were prescribed with ocular hypotensive monotherapy between September 1996 and August 2002.
1,182 patients were included. The Kaplan Meier life table analysis showed that latanoprost was continued longest among the groups for the first year of therapy (p=0.02). A significant difference existed between groups in the final intraocular pressure for latanoprost (17.3+/-3.9, N=357), for bimatoprost (18.0+/-3.6, N=146), and for the beta-blockers (17.9+/-3.7, N=335) (p=<0.0001). The average number of visits was statistically higher for beta-blockers (3.3), compared to latanoprost (2.9) and bimatoprost (3.1) (p=0.01). Further, the mean number of medicine changes was greater for bimatoprost (0.45) and beta-blockers (0.47) than for latanoprost (0.27) (p=0.0008). The cost of visits and medications was lowest for beta-blockers ($119.3+/-$78.9) and highest for bimatoprost ($163.8+/-$51.2) (p<0.0001).
Patients were more persistent with latanoprost and demonstrated lower intraocular pressure, fewer visits, and fewer medicine changes when compared to bimatoprost or beta-blocker therapy. In contrast, the beta-blocker group provided lower overall cost.</description><identifier>ISSN: 1080-7683</identifier><identifier>EISSN: 1557-7732</identifier><identifier>DOI: 10.1089/jop.2004.20.383</identifier><identifier>PMID: 15650513</identifier><language>eng</language><publisher>Larchmont, NY: Liebert</publisher><subject>Adrenergic beta-Antagonists - economics ; Aged ; Amides ; Antihypertensive Agents - economics ; Bimatoprost ; Biological and medical sciences ; Birth control ; Cloprostenol - analogs & derivatives ; Drug Costs ; Economics, Pharmaceutical ; Female ; Glaucoma and intraocular pressure ; Glaucoma, Open-Angle - drug therapy ; Glaucoma, Open-Angle - economics ; Gynecology. Andrology. Obstetrics ; Health Care Costs ; Humans ; Intraocular Pressure - drug effects ; Lipids - economics ; Male ; Medical sciences ; Middle Aged ; Ocular Hypertension - drug therapy ; Ocular Hypertension - economics ; Office Visits ; Ophthalmology ; Other methods of contraception. Sterilization ; Patient Compliance ; Prostaglandins F, Synthetic - economics ; Retinopathies ; Retrospective Studies ; Safety</subject><ispartof>Journal of ocular pharmacology and therapeutics, 2004-10, Vol.20 (5), p.383-392</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c238t-b954e1108258d36c9410d0752ae867bd287061a3c25914068c87965417ecf44d3</citedby><cites>FETCH-LOGICAL-c238t-b954e1108258d36c9410d0752ae867bd287061a3c25914068c87965417ecf44d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3029,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16232387$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15650513$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DAY, Douglas G</creatorcontrib><creatorcontrib>SCHACKNOW, Paul N</creatorcontrib><creatorcontrib>SHARPE, Elizabeth D</creatorcontrib><creatorcontrib>ELLYN, John C</creatorcontrib><creatorcontrib>KULZE, John C</creatorcontrib><creatorcontrib>THRELKELD, Anisa B</creatorcontrib><creatorcontrib>JONES, Evan D</creatorcontrib><creatorcontrib>BROWN, Reay H</creatorcontrib><creatorcontrib>JENKINS, Jessica N</creatorcontrib><creatorcontrib>STEWART, William C</creatorcontrib><title>A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension</title><title>Journal of ocular pharmacology and therapeutics</title><addtitle>J Ocul Pharmacol Ther</addtitle><description>The aim of this study was to evaluate differences in the persistency and treatment costs for latanoprost, bimatoprost, or beta-blockers in open-angle glaucoma or ocular hypertensive patients.
This study was a retrospective, multicenter, parallel, active-controlled comparison of patients who were prescribed with ocular hypotensive monotherapy between September 1996 and August 2002.
1,182 patients were included. The Kaplan Meier life table analysis showed that latanoprost was continued longest among the groups for the first year of therapy (p=0.02). A significant difference existed between groups in the final intraocular pressure for latanoprost (17.3+/-3.9, N=357), for bimatoprost (18.0+/-3.6, N=146), and for the beta-blockers (17.9+/-3.7, N=335) (p=<0.0001). The average number of visits was statistically higher for beta-blockers (3.3), compared to latanoprost (2.9) and bimatoprost (3.1) (p=0.01). Further, the mean number of medicine changes was greater for bimatoprost (0.45) and beta-blockers (0.47) than for latanoprost (0.27) (p=0.0008). The cost of visits and medications was lowest for beta-blockers ($119.3+/-$78.9) and highest for bimatoprost ($163.8+/-$51.2) (p<0.0001).
Patients were more persistent with latanoprost and demonstrated lower intraocular pressure, fewer visits, and fewer medicine changes when compared to bimatoprost or beta-blocker therapy. In contrast, the beta-blocker group provided lower overall cost.</description><subject>Adrenergic beta-Antagonists - economics</subject><subject>Aged</subject><subject>Amides</subject><subject>Antihypertensive Agents - economics</subject><subject>Bimatoprost</subject><subject>Biological and medical sciences</subject><subject>Birth control</subject><subject>Cloprostenol - analogs & derivatives</subject><subject>Drug Costs</subject><subject>Economics, Pharmaceutical</subject><subject>Female</subject><subject>Glaucoma and intraocular pressure</subject><subject>Glaucoma, Open-Angle - drug therapy</subject><subject>Glaucoma, Open-Angle - economics</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Health Care Costs</subject><subject>Humans</subject><subject>Intraocular Pressure - drug effects</subject><subject>Lipids - economics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ocular Hypertension - drug therapy</subject><subject>Ocular Hypertension - economics</subject><subject>Office Visits</subject><subject>Ophthalmology</subject><subject>Other methods of contraception. Sterilization</subject><subject>Patient Compliance</subject><subject>Prostaglandins F, Synthetic - economics</subject><subject>Retinopathies</subject><subject>Retrospective Studies</subject><subject>Safety</subject><issn>1080-7683</issn><issn>1557-7732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkctu1TAQhi1ERcuBNTvkDazIqS_xJcuq4iZVYlPW0cRxWhfHDrEjdB6i79w56kHdjD3yPzP-5ifkA2d7zmx3-ZCXvWCsxbCXVr4iF1wp0xgjxWu8M8sao608J29LeWCMS6b5G3LOlVZMcXlBHq_o4tcSSvXJHSikkXqXU56DwwTiAZ9onmiECikvay71Cx3CDPV_klc6-ArNELP7g61oSHSBGnyqhf4L9Z7mxacG0l309C7C5vIMx6rstggrvT_gB3B6CTm9I2cTxOLfn84d-f3t6-31j-bm1_ef11c3jRPS1mboVOs50gllR6ld13I2MqMEeKvNMAprkBOkE6rjLdPWWdNp1XLj3dS2o9yRz899keHv5kvt51CcjxGSz1vptRFCdLjFHbl8FjqELauf-mVF-PXQc9YfHejRgf7oAIYeHcCKj6fW2zD78UV_WjkKPp0EUBzEaYXkQnnRaSER0sgntpqQpg</recordid><startdate>200410</startdate><enddate>200410</enddate><creator>DAY, Douglas G</creator><creator>SCHACKNOW, Paul N</creator><creator>SHARPE, Elizabeth D</creator><creator>ELLYN, John C</creator><creator>KULZE, John C</creator><creator>THRELKELD, Anisa B</creator><creator>JONES, Evan D</creator><creator>BROWN, Reay H</creator><creator>JENKINS, Jessica N</creator><creator>STEWART, William C</creator><general>Liebert</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200410</creationdate><title>A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension</title><author>DAY, Douglas G ; SCHACKNOW, Paul N ; SHARPE, Elizabeth D ; ELLYN, John C ; KULZE, John C ; THRELKELD, Anisa B ; JONES, Evan D ; BROWN, Reay H ; JENKINS, Jessica N ; STEWART, William C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c238t-b954e1108258d36c9410d0752ae867bd287061a3c25914068c87965417ecf44d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adrenergic beta-Antagonists - economics</topic><topic>Aged</topic><topic>Amides</topic><topic>Antihypertensive Agents - economics</topic><topic>Bimatoprost</topic><topic>Biological and medical sciences</topic><topic>Birth control</topic><topic>Cloprostenol - analogs & derivatives</topic><topic>Drug Costs</topic><topic>Economics, Pharmaceutical</topic><topic>Female</topic><topic>Glaucoma and intraocular pressure</topic><topic>Glaucoma, Open-Angle - drug therapy</topic><topic>Glaucoma, Open-Angle - economics</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Health Care Costs</topic><topic>Humans</topic><topic>Intraocular Pressure - drug effects</topic><topic>Lipids - economics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ocular Hypertension - drug therapy</topic><topic>Ocular Hypertension - economics</topic><topic>Office Visits</topic><topic>Ophthalmology</topic><topic>Other methods of contraception. Sterilization</topic><topic>Patient Compliance</topic><topic>Prostaglandins F, Synthetic - economics</topic><topic>Retinopathies</topic><topic>Retrospective Studies</topic><topic>Safety</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DAY, Douglas G</creatorcontrib><creatorcontrib>SCHACKNOW, Paul N</creatorcontrib><creatorcontrib>SHARPE, Elizabeth D</creatorcontrib><creatorcontrib>ELLYN, John C</creatorcontrib><creatorcontrib>KULZE, John C</creatorcontrib><creatorcontrib>THRELKELD, Anisa B</creatorcontrib><creatorcontrib>JONES, Evan D</creatorcontrib><creatorcontrib>BROWN, Reay H</creatorcontrib><creatorcontrib>JENKINS, Jessica N</creatorcontrib><creatorcontrib>STEWART, William C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of ocular pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DAY, Douglas G</au><au>SCHACKNOW, Paul N</au><au>SHARPE, Elizabeth D</au><au>ELLYN, John C</au><au>KULZE, John C</au><au>THRELKELD, Anisa B</au><au>JONES, Evan D</au><au>BROWN, Reay H</au><au>JENKINS, Jessica N</au><au>STEWART, William C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension</atitle><jtitle>Journal of ocular pharmacology and therapeutics</jtitle><addtitle>J Ocul Pharmacol Ther</addtitle><date>2004-10</date><risdate>2004</risdate><volume>20</volume><issue>5</issue><spage>383</spage><epage>392</epage><pages>383-392</pages><issn>1080-7683</issn><eissn>1557-7732</eissn><abstract>The aim of this study was to evaluate differences in the persistency and treatment costs for latanoprost, bimatoprost, or beta-blockers in open-angle glaucoma or ocular hypertensive patients.
This study was a retrospective, multicenter, parallel, active-controlled comparison of patients who were prescribed with ocular hypotensive monotherapy between September 1996 and August 2002.
1,182 patients were included. The Kaplan Meier life table analysis showed that latanoprost was continued longest among the groups for the first year of therapy (p=0.02). A significant difference existed between groups in the final intraocular pressure for latanoprost (17.3+/-3.9, N=357), for bimatoprost (18.0+/-3.6, N=146), and for the beta-blockers (17.9+/-3.7, N=335) (p=<0.0001). The average number of visits was statistically higher for beta-blockers (3.3), compared to latanoprost (2.9) and bimatoprost (3.1) (p=0.01). Further, the mean number of medicine changes was greater for bimatoprost (0.45) and beta-blockers (0.47) than for latanoprost (0.27) (p=0.0008). The cost of visits and medications was lowest for beta-blockers ($119.3+/-$78.9) and highest for bimatoprost ($163.8+/-$51.2) (p<0.0001).
Patients were more persistent with latanoprost and demonstrated lower intraocular pressure, fewer visits, and fewer medicine changes when compared to bimatoprost or beta-blocker therapy. In contrast, the beta-blocker group provided lower overall cost.</abstract><cop>Larchmont, NY</cop><pub>Liebert</pub><pmid>15650513</pmid><doi>10.1089/jop.2004.20.383</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1080-7683 |
| ispartof | Journal of ocular pharmacology and therapeutics, 2004-10, Vol.20 (5), p.383-392 |
| issn | 1080-7683 1557-7732 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67222977 |
| source | Mary Ann Liebert Online Subscription; MEDLINE |
| subjects | Adrenergic beta-Antagonists - economics Aged Amides Antihypertensive Agents - economics Bimatoprost Biological and medical sciences Birth control Cloprostenol - analogs & derivatives Drug Costs Economics, Pharmaceutical Female Glaucoma and intraocular pressure Glaucoma, Open-Angle - drug therapy Glaucoma, Open-Angle - economics Gynecology. Andrology. Obstetrics Health Care Costs Humans Intraocular Pressure - drug effects Lipids - economics Male Medical sciences Middle Aged Ocular Hypertension - drug therapy Ocular Hypertension - economics Office Visits Ophthalmology Other methods of contraception. Sterilization Patient Compliance Prostaglandins F, Synthetic - economics Retinopathies Retrospective Studies Safety |
| title | A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T11%3A07%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20persistency%20and%20economic%20analysis%20of%20latanoprost,%20bimatoprost,%20or%20beta-blockers%20in%20patients%20with%20open-angle%20glaucoma%20or%20ocular%20hypertension&rft.jtitle=Journal%20of%20ocular%20pharmacology%20and%20therapeutics&rft.au=DAY,%20Douglas%20G&rft.date=2004-10&rft.volume=20&rft.issue=5&rft.spage=383&rft.epage=392&rft.pages=383-392&rft.issn=1080-7683&rft.eissn=1557-7732&rft_id=info:doi/10.1089/jop.2004.20.383&rft_dat=%3Cproquest_cross%3E67222977%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67222977&rft_id=info:pmid/15650513&rfr_iscdi=true |